Haptoglobin Genotype Test (887)

This test identifies individuals with diabetes or advanced kidney disease who may benefit from vitamin E supplementation. Those individuals with the haptoglobin 2/2 variant are at risk for accelerated oxidative damage due to delayed clearance of haptoglobin-hemoglobin complexes. Vitamin E supplementation (400 IU daily) in those individuals has been demonstrated to reduce the risk of CVD events and CVD death.

• No increased CVD risk other than from risk associated with underlying conditions
• Genotype 1/1
• Genotype 1/2
• 3-Fold increased CVD risk in patients with diabetes or kidney disease1
• Genotype 2/2

References:

1. Cahill LE, Levy AP, Chiuve SE, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol 2013; 61:728–37.

Methodology - Real-time polymerase chain reaction (PCR)